Prevention of intrahepatic hepatocarcinoma recurrence in patients with viral cirrhosis: two potential options.
Mortality due to hepatocellular carcinoma (HCC) is still high, because of its development in liver with impaired function due to underlying cirrhosis, of its chemoresistance and of its high rate of recurrence. Liver transplantation is considered the most efficacious treatment for patients with HCC. However, the low availability of organs limits the offer of this option to all candidates. Furthermore, liver transplantation is not lacking in risk of tumour recurrence. Other curative options include surgical resection and ablation using percutaneous techniques. Such approaches give similar and satisfactory survival rates, providing that patient selection is optimal in terms of tumour size and liver function. Since even in the presence of a radical therapeutic result this cancer maintains a high tendency for local recurrence, it is very important to explore the adjuvant ways to increase the disease-free survival in patients surgically treated. Treatment with interferon a and intrahepatic injection of (131)-Iodine labelled lipiodol ((131)I-Lipiodol) are instead showing encouraging results. This review presents a concise update on this issue.
Tabone
M
M
Unit of Gastroenterology, Mauriziano Umberto I Hospital, Largo Turati 62, 10128 Turin, Italy. m.tabone@virgilio.it
Pellicano
R
R
D000998:Antiviral Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications* / Q000821:virology*; D008113:Liver Neoplasms / Q000209:etiology* / Q000517:prevention & control*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*
D000998:Antiviral Agents; D016898:Interferon-alpha